WO2001028589A2 - Formkörper mit amphiphilen äusseren phase und lipophilen inneren phase - Google Patents
Formkörper mit amphiphilen äusseren phase und lipophilen inneren phase Download PDFInfo
- Publication number
- WO2001028589A2 WO2001028589A2 PCT/EP2000/010113 EP0010113W WO0128589A2 WO 2001028589 A2 WO2001028589 A2 WO 2001028589A2 EP 0010113 W EP0010113 W EP 0010113W WO 0128589 A2 WO0128589 A2 WO 0128589A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- shaped body
- outer phase
- body according
- phase
- water
- Prior art date
Links
- 239000008385 outer phase Substances 0.000 title claims description 35
- 239000008384 inner phase Substances 0.000 title claims description 13
- 239000000126 substance Substances 0.000 claims abstract description 20
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 11
- 229920000728 polyester Polymers 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 35
- 229920000642 polymer Polymers 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 21
- 238000002844 melting Methods 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 230000007935 neutral effect Effects 0.000 claims description 13
- 230000008018 melting Effects 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 235000013871 bee wax Nutrition 0.000 claims description 9
- 239000012166 beeswax Substances 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 9
- 229920001400 block copolymer Polymers 0.000 claims description 8
- 150000002191 fatty alcohols Chemical class 0.000 claims description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- 239000000155 melt Substances 0.000 claims description 8
- 229920000570 polyether Polymers 0.000 claims description 8
- 239000004952 Polyamide Substances 0.000 claims description 7
- 229920001993 poloxamer 188 Polymers 0.000 claims description 7
- 229940044519 poloxamer 188 Drugs 0.000 claims description 7
- 229920001992 poloxamer 407 Polymers 0.000 claims description 7
- 229940044476 poloxamer 407 Drugs 0.000 claims description 7
- 229920002647 polyamide Polymers 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000001993 wax Substances 0.000 claims description 6
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 229960003511 macrogol Drugs 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 210000002445 nipple Anatomy 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- 229920002507 Poloxamer 124 Polymers 0.000 claims description 3
- 229920002511 Poloxamer 237 Polymers 0.000 claims description 3
- 229920002517 Poloxamer 338 Polymers 0.000 claims description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 claims description 3
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004150 aciclovir Drugs 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 229960002537 betamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 3
- 238000001125 extrusion Methods 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- 229960000282 metronidazole Drugs 0.000 claims description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229940093448 poloxamer 124 Drugs 0.000 claims description 3
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002544 virustatic Substances 0.000 claims description 3
- 230000001790 virustatic effect Effects 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 239000004815 dispersion polymer Substances 0.000 claims description 2
- 230000009969 flowable effect Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 claims description 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 239000011049 pearl Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 2
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000002745 poly(ortho ester) Substances 0.000 claims description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000000622 polydioxanone Substances 0.000 claims description 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 2
- 229920002959 polymer blend Polymers 0.000 claims description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229920001169 thermoplastic Polymers 0.000 claims description 2
- 239000004416 thermosoftening plastic Substances 0.000 claims description 2
- 235000013861 fat-free Nutrition 0.000 claims 3
- 125000000373 fatty alcohol group Chemical group 0.000 claims 1
- 125000005457 triglyceride group Chemical group 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 abstract description 5
- 238000001816 cooling Methods 0.000 abstract description 4
- 238000003825 pressing Methods 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 229920001477 hydrophilic polymer Polymers 0.000 abstract description 2
- 238000010297 mechanical methods and process Methods 0.000 abstract description 2
- 238000005452 bending Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 239000012071 phase Substances 0.000 description 9
- 239000003925 fat Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000000465 moulding Methods 0.000 description 5
- 230000002924 anti-infective effect Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000855 fungicidal effect Effects 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- -1 polytrimethylene Polymers 0.000 description 3
- 230000003253 viricidal effect Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000008293 association colloid Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001723 curing Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 210000001559 fluids and secretion Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000980 poly(hydroxybutyrate-co-hydroxyvalerate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/001—Combinations of extrusion moulding with other shaping operations
- B29C48/0022—Combinations of extrusion moulding with other shaping operations combined with cutting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
- B29C48/05—Filamentary, e.g. strands
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mechanical Engineering (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Extrusion Moulding Of Plastics Or The Like (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Cosmetics (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001531417A JP2003512337A (ja) | 1999-10-15 | 2000-10-13 | 両親媒性外部相と親油性内部相とよりなる成形体 |
AT00974391T ATE246916T1 (de) | 1999-10-15 | 2000-10-13 | Formkörper mit einer amphiphilen äusseren phase und einer lipophilen inneren phase |
EP00974391A EP1220656B1 (de) | 1999-10-15 | 2000-10-13 | Formkörper mit einer amphiphilen äusseren phase und einer lipophilen inneren phase |
AU12719/01A AU781999B2 (en) | 1999-10-15 | 2000-10-13 | Shaped body and method for production of said body |
DE50003306T DE50003306D1 (de) | 1999-10-15 | 2000-10-13 | Formkörper mit einer amphiphilen äusseren phase und einer lipophilen inneren phase |
DK00974391T DK1220656T3 (da) | 1999-10-15 | 2000-10-13 | Formet legeme med en amfifil ydre fase og en lipofil indre fase |
NZ518831A NZ518831A (en) | 1999-10-15 | 2000-10-13 | Shaped body comprising an amphiphilic outer phase and a lipophilic inner phase |
US11/143,609 US7541047B2 (en) | 1999-10-15 | 2005-06-03 | Method for production of shaped body for treating wounds in milk producing animals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19949897.0 | 1999-10-15 | ||
DE19949897A DE19949897A1 (de) | 1999-10-15 | 1999-10-15 | Formkörper und Verfahren zu dessen Herstellung |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/143,609 Continuation US7541047B2 (en) | 1999-10-15 | 2005-06-03 | Method for production of shaped body for treating wounds in milk producing animals |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001028589A2 true WO2001028589A2 (de) | 2001-04-26 |
WO2001028589A3 WO2001028589A3 (de) | 2002-04-11 |
Family
ID=7925862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/010113 WO2001028589A2 (de) | 1999-10-15 | 2000-10-13 | Formkörper mit amphiphilen äusseren phase und lipophilen inneren phase |
Country Status (10)
Country | Link |
---|---|
US (3) | US7541047B2 (de) |
EP (1) | EP1220656B1 (de) |
JP (1) | JP2003512337A (de) |
AT (1) | ATE246916T1 (de) |
AU (1) | AU781999B2 (de) |
DE (2) | DE19949897A1 (de) |
DK (1) | DK1220656T3 (de) |
ES (1) | ES2204714T3 (de) |
NZ (1) | NZ518831A (de) |
WO (1) | WO2001028589A2 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010030995A2 (en) * | 2008-09-15 | 2010-03-18 | Cv Ingenuity | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8734825B2 (en) | 2008-09-15 | 2014-05-27 | Covidien Lp | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9034362B2 (en) | 2008-09-15 | 2015-05-19 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8128951B2 (en) | 2008-09-15 | 2012-03-06 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8685381B2 (en) | 2010-10-23 | 2014-04-01 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
US8968755B2 (en) | 2010-10-23 | 2015-03-03 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
JP6252202B2 (ja) * | 2014-01-23 | 2017-12-27 | ライオン株式会社 | 口腔内塗布用固形スティック製剤 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB887872A (en) * | 1958-06-25 | 1962-01-24 | Upjohn Co | Improvements in or relating to pharmaceutical preparations |
US4344968A (en) * | 1978-12-09 | 1982-08-17 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical vehicle |
US4347237A (en) * | 1981-03-02 | 1982-08-31 | Evenstad Kenneth L | Lower fatty acid glyceride high-HLB lubricating suppository and method for making and using the same |
EP0094513A2 (de) * | 1982-05-14 | 1983-11-23 | Akzo GmbH | Wirkstoff enthaltender Körper für die Langzeitabgabe |
EP0103995A2 (de) * | 1982-08-24 | 1984-03-28 | Cilag Ag | Medizinisches Zäpfchen |
US4874774A (en) * | 1983-11-17 | 1989-10-17 | Nippon Shinyaku Co., Ltd. | Nifedipine compositions and the production thereof |
US5393738A (en) * | 1986-05-27 | 1995-02-28 | Sandoz, Ltd. | Pharmaceutical compositions containing octreotide and excipients for oral or rectal administration |
EP0709085A1 (de) * | 1994-09-30 | 1996-05-01 | Takeda Chemical Industries, Ltd. | Präparat mit verzögerter Wirkstoffabgabe |
WO1996014059A1 (en) * | 1994-11-03 | 1996-05-17 | Euro-Celtique S.A. | Pharmaceutical composition containing a fusible carrier and method for producing the same |
EP0748630A1 (de) * | 1994-12-29 | 1996-12-18 | Mochida Pharmaceutical Co., Ltd. | Urinastatin enthaltende zäpfchen |
US5700486A (en) * | 1990-11-22 | 1997-12-23 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
WO2000003660A1 (en) * | 1998-07-17 | 2000-01-27 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3756238A (en) * | 1971-03-24 | 1973-09-04 | Kimberly Clark Co | Self-lubricating compound for use in hygienic and medical applications, and coated tampons and suppositories made therefrom |
DE2553026A1 (de) * | 1974-12-04 | 1976-06-10 | Schlueter Edelfett | Neue formulierungen |
JPS6030650B2 (ja) * | 1979-10-26 | 1985-07-17 | 日本油脂株式会社 | 座薬基剤組成物 |
US5248700A (en) | 1982-05-14 | 1993-09-28 | Akzo Nv | Active agent containing solid structures for prolonged release of active agents |
DE3230602A1 (de) * | 1982-08-18 | 1984-02-23 | Kenneth L. 55391 Wayzata Minn. Evenstad | Als gleitmittel wirkendes suppositorium, verfahren fuer dessen herstellung und anwendung desselben |
US4698359A (en) | 1982-08-24 | 1987-10-06 | Cilag, Ag | Medicated suppository |
US5240712A (en) * | 1987-07-17 | 1993-08-31 | The Boots Company Plc | Therapeutic agents |
US4935248A (en) * | 1988-07-28 | 1990-06-19 | Albert L. Jacobs | Antimicrobial veterinary compositions and methods |
US5874479A (en) | 1991-03-01 | 1999-02-23 | Warner-Lambert Company | Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same |
ATE159426T1 (de) * | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
TW359614B (en) * | 1993-08-31 | 1999-06-01 | Takeda Chemical Industries Ltd | Composition containing benzimidazole compounds for rectal administration |
-
1999
- 1999-10-15 DE DE19949897A patent/DE19949897A1/de not_active Withdrawn
-
2000
- 2000-10-13 DK DK00974391T patent/DK1220656T3/da active
- 2000-10-13 NZ NZ518831A patent/NZ518831A/en not_active IP Right Cessation
- 2000-10-13 AU AU12719/01A patent/AU781999B2/en not_active Ceased
- 2000-10-13 AT AT00974391T patent/ATE246916T1/de active
- 2000-10-13 WO PCT/EP2000/010113 patent/WO2001028589A2/de active IP Right Grant
- 2000-10-13 EP EP00974391A patent/EP1220656B1/de not_active Expired - Lifetime
- 2000-10-13 DE DE50003306T patent/DE50003306D1/de not_active Expired - Lifetime
- 2000-10-13 JP JP2001531417A patent/JP2003512337A/ja not_active Withdrawn
- 2000-10-13 ES ES00974391T patent/ES2204714T3/es not_active Expired - Lifetime
-
2005
- 2005-06-03 US US11/143,609 patent/US7541047B2/en not_active Expired - Fee Related
-
2008
- 2008-11-17 US US12/292,300 patent/US20090074707A1/en not_active Abandoned
-
2009
- 2009-05-12 US US12/453,460 patent/US20090218731A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB887872A (en) * | 1958-06-25 | 1962-01-24 | Upjohn Co | Improvements in or relating to pharmaceutical preparations |
US4344968A (en) * | 1978-12-09 | 1982-08-17 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical vehicle |
US4347237A (en) * | 1981-03-02 | 1982-08-31 | Evenstad Kenneth L | Lower fatty acid glyceride high-HLB lubricating suppository and method for making and using the same |
EP0094513A2 (de) * | 1982-05-14 | 1983-11-23 | Akzo GmbH | Wirkstoff enthaltender Körper für die Langzeitabgabe |
EP0103995A2 (de) * | 1982-08-24 | 1984-03-28 | Cilag Ag | Medizinisches Zäpfchen |
US4874774A (en) * | 1983-11-17 | 1989-10-17 | Nippon Shinyaku Co., Ltd. | Nifedipine compositions and the production thereof |
US5393738A (en) * | 1986-05-27 | 1995-02-28 | Sandoz, Ltd. | Pharmaceutical compositions containing octreotide and excipients for oral or rectal administration |
US5700486A (en) * | 1990-11-22 | 1997-12-23 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
EP0709085A1 (de) * | 1994-09-30 | 1996-05-01 | Takeda Chemical Industries, Ltd. | Präparat mit verzögerter Wirkstoffabgabe |
WO1996014059A1 (en) * | 1994-11-03 | 1996-05-17 | Euro-Celtique S.A. | Pharmaceutical composition containing a fusible carrier and method for producing the same |
EP0748630A1 (de) * | 1994-12-29 | 1996-12-18 | Mochida Pharmaceutical Co., Ltd. | Urinastatin enthaltende zäpfchen |
WO2000003660A1 (en) * | 1998-07-17 | 2000-01-27 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
Non-Patent Citations (1)
Title |
---|
REGDON G ET AL: "FORMULATION AND IN VITRO STUDY OF THEOPHYLLNE CONTAINING SUPPOSITORIES" PHARMAZIE,DD,VEB VERLAG VOLK UND GESUNDHEIT. BERLIN, Bd. 51, Nr. 5, 1. Mai 1996 (1996-05-01), Seiten 347-352, XP000582508 ISSN: 0031-7144 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9603973B2 (en) | 2008-09-15 | 2017-03-28 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
WO2010030995A3 (en) * | 2008-09-15 | 2010-05-14 | Cv Ingenuity | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface body lumens |
AU2009291552B2 (en) * | 2008-09-15 | 2014-04-03 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8734825B2 (en) | 2008-09-15 | 2014-05-27 | Covidien Lp | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9034362B2 (en) | 2008-09-15 | 2015-05-19 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9132211B2 (en) | 2008-09-15 | 2015-09-15 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
WO2010030995A2 (en) * | 2008-09-15 | 2010-03-18 | Cv Ingenuity | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10046093B2 (en) | 2008-09-15 | 2018-08-14 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10117970B2 (en) | 2008-09-15 | 2018-11-06 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10314948B2 (en) | 2008-09-15 | 2019-06-11 | The Spectranetics Coporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10987452B2 (en) | 2008-09-15 | 2021-04-27 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
Also Published As
Publication number | Publication date |
---|---|
ATE246916T1 (de) | 2003-08-15 |
US20090074707A1 (en) | 2009-03-19 |
US20050226903A1 (en) | 2005-10-13 |
EP1220656A2 (de) | 2002-07-10 |
US7541047B2 (en) | 2009-06-02 |
WO2001028589A3 (de) | 2002-04-11 |
DE19949897A1 (de) | 2001-04-19 |
AU1271901A (en) | 2001-04-30 |
JP2003512337A (ja) | 2003-04-02 |
NZ518831A (en) | 2003-09-26 |
DK1220656T3 (da) | 2003-12-01 |
DE50003306D1 (de) | 2003-09-18 |
ES2204714T3 (es) | 2004-05-01 |
EP1220656B1 (de) | 2003-08-13 |
AU781999B2 (en) | 2005-06-23 |
US20090218731A1 (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0311065B1 (de) | Implantierbares, biologisch abbaubares Wirkstofffreigabesystem | |
DE69926504T2 (de) | Zubereitungen zur kontrollierten freisetzung mit mehrschichtstruktur | |
DE69918275T2 (de) | Flüssige polymerlosung zur kontrollierten freisetzung von bioaktiven substanzen | |
DE60003803T2 (de) | Trockene formbare arzneistoffformulierung | |
DE69309701T3 (de) | Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung periodontaler erkrankungen | |
US7541047B2 (en) | Method for production of shaped body for treating wounds in milk producing animals | |
DD146548A5 (de) | Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin | |
WO2000057854A2 (de) | Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen | |
DE1948019B2 (de) | Verfahren zur Herstellung von geformten Arzneizubereitungen mit Depotwirkung | |
DE69531773T2 (de) | Vorrichtung zur verabreichung von nützlichen stoffen an wiederkäuer | |
EP1171101B1 (de) | Verfahren zur herstellung einer wasserunlöslichen amorphen retardmatrix | |
WO2001000175A1 (de) | Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen | |
DE10044545A1 (de) | Retardpartikeldispersion | |
DE60126332T2 (de) | Wärmeformbare feste pharmazeutische zusammensetzung für die kontrollierte freigabe von ivabradin | |
EP3600243A1 (de) | Extrudierte depotform zur anhaltenden wirkstofffreisetzung | |
DE4021678A1 (de) | Verfahren zur herstellung klein dimensionierter formkoerper mit hohem etofibrat-gehalt und kontrollierter wirkstoff-freisetzung, deren verwendung und daraus bestehende oral verabreichbare applikationsformen | |
EP1850830B1 (de) | Suppositorium zur bindung von reaktiven sauerstoffverbindungen im körper von menschen und tieren | |
EP0108882B1 (de) | Presslinge mit retardierter Wirkstofffreisetzung und Verfahren zu deren Herstellung | |
DE2459391C3 (de) | Medizinische feste Augeneinlage | |
EP0332094A1 (de) | Oral verabreichbares System zur kontrollierten Freigabe von Wirkstoffen | |
DE60127139T2 (de) | Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial | |
DE60020871T2 (de) | Formulierungen mit verlängerter freisetzung zur implantation | |
EP3943071A1 (de) | Zusammensetzung, enthaltend natürliche lipophile verbindungen, verwendung der zusammensetzung und verfahren zur herstellung der zusammensetzung | |
DE60112117T2 (de) | Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril | |
Alam et al. | Effect of different excipients on the release of vinpocetine from biodegradable polymeric implants of chitosan and sodium alginate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 531417 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000974391 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 518831 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12719/01 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2000974391 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10110431 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000974391 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 518831 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 518831 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 12719/01 Country of ref document: AU |